Glycan variability on a recombinant IgG antibody transiently produced in HEK-293E cells

New Biotechnology

Volumn 29, Issue 4, 2012, Pages 471-476

  Nallet, Sophie ^a   Fornelli, Luca ^a   Schmitt, Simone ^a,b   Parra, Julien ^a,c   Baldi, Lucia ^a   Tsybin, Yury O ^a   Wurm, Florian M ^a  

^a EPFL   (Switzerland)

^b Delenex Therapeutics AG   (Switzerland)

^c UNIVERSITÉ D EVRY VAL D ESSONNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BATCH PROCESS; EXPERIMENTAL DATA; GLYCANS; GLYCOFORMS; INTACT PROTEINS; N-GLYCOSYLATION; PROTEIN GLYCOSYLATION; RELATIVE DEVIATIONS; SPECIFIC PRODUCTIVITY; TRANSIENT GENE EXPRESSIONS; VOLUMETRIC YIELD;

ANTIBODIES; BATCH DATA PROCESSING; CELL CULTURE; ESTERIFICATION; GENE EXPRESSION; GLYCOSYLATION; MASS SPECTROMETRY;

RECOMBINANT PROTEINS;

GLYCAN; IMMUNOGLOBULIN G ANTIBODY; RECOMBINANT ANTIBODY;

ANIMAL CELL; ARTICLE; BATCH PROCESS; GEL PERMEATION CHROMATOGRAPHY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; MASS SPECTROMETRY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; TRANSIENT EXPRESSION;

AMINO ACID SEQUENCE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLYCOPEPTIDES; GLYCOSYLATION; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN G; POLYSACCHARIDES; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84860376587     PISSN: 18716784     EISSN: 18764347     Source Type: Journal    
DOI: 10.1016/j.nbt.2012.02.003     Document Type: Article

References (22)

1. Walsh G. Biopharmaceutical benchmarks 2010. Nat. Biotechnol. 2010, 28:917-924.
2. Wurm F.M. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 2004, 22:1393-1398.
3. Baldi L., et al. Recombinant protein production by large-scale transient gene expression in mammalian cells: state of the art and future perspectives. Biotechnol. Lett. 2007, 29:677-684.
4. Geisse S., Fux C. Recombinant protein production by transient gene transfer into mammalian cells. Methods Enzymol. 2009, 463:223-238.
5. Pham P.L., et al. Large-scale transfection of mammalian cells for the fast production of recombinant protein. Mol. Biotechnol. 2006, 34:225-237.
6. Muller N., et al. Orbital shaker technology for the cultivation of mammalian cells in suspension. Biotechnol. Bioeng. 2005, 89:400-406.
7. Backliwal G., et al. High-density transfection with HEK-293 cells allows doubling of transient titers and removes need for a priori DNA complex formation with PEI. Biotechnol. Bioeng. 2008, 99:721-727.
8. Rajendra Y., et al. A simple high-yielding process for transient gene expression in CHO cells. J. Biotechnol. 2011, 153:22-26.
9. Meissner P., et al. Transient gene expression: recombinant protein production with suspension-adapted HEK293-EBNA cells. Biotechnol. Bioeng. 2001, 75:197-203.
10. Miescher S., et al. A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcgammaRIIA and FcgammaIIIA genes. Blood 2004, 103:4028-4035.
11. Rebecchi K.R., et al. Label-free quantitation: a new glycoproteomics approach. J. Am. Soc. Mass Spectrom. 2009, 20:1048-1059.
12. Kabat, E.A. et al. (1991) Sequences of Proteins of Immunological Interest (5th edn), NIH Publication n. 91-3242.
13. Go E.P., et al. GlycoPep DB: a tool for glycopeptide analysis using a Smart Search. Anal. Chem. 2007, 79:1708-1713.
14. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 2009, 8:226-234.
15. Raju T.S., et al. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 2000, 10:477-486.
16. Stadlmann J., et al. Analysis of immunoglobulin glycosylation by LC-ESI-MS of glycopeptides and oligosaccharides. Proteomics 2008, 8:2858-2871.
17. Zhang Z., et al. Mass spectrometry for structural characterization of therapeutic antibodies. Mass Spectrom. Rev. 2009, 28:147-176.
18. Krapp S., et al. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J. Mol. Biol. 2003, 325:979-989.
19. Ferrara C., et al. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol. Bioeng. 2006, 93:851-861.
20. Galbraith D.J., et al. Control of culture environment for improved polyethylenimine-mediated transient production of recombinant monoclonal antibodies by CHO cells. Biotechnol. Prog. 2006, 22:753-762.
21. Flynn G.C., et al. Naturally occurring glycan forms of human immunoglobulins G1 and G2. Mol. Immunol. 2010, 47:2074-2082.
22. Scherer H.U., et al. Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum. 2010, 62:1620-1629.